B- cell lymphoproliferative disorders Flashcards

1
Q

List the differential diagnosis for CD5+ LPDs and how to differentiate between them

A

1) CLL.
- Most common CD5+ LPD
- Classic morphology: small, mature, monomorphic lymphocytes with clumped nuclear chromatin, round nucleus, high N:C ratio and mildly basophilic cytoplasm.
- Focal nodular or interstitial pattern of infiltration on trephine. Diffuse infiltration and expanded proliferation centres in high risk disease.
- Classic immunophenotype: CD5+ CD19+ B cells. Weak CD20, CD22 and SIg. CD79a weak or absent. CD23 and CD200+
- FMC-, LEF1+

2) MCL.
- Second most common CD5+ LPD
- Classic morphology: small, mature, monomorphic lymphocytes with condensed nuclear chromatin a high N:C ratio and mildly basophilic cytoplasm. Nuclear clefts commonly seen. Many variants (small cell, marginal, pleomorphic, blastic)
- Nodular, paratrabecular, interstitial or diffuse infiltration on trephine.
- Classic immunophenotype: CD5+, CD19+ B cells that are CD20, CD22, CD79a and SIg positive. CD23 and CD200 negative .
- CCND1 and SOX11 positive in classic cases.
- t(11;14) translocation identified on FISH.

3) B-PLL
- CD5 positivity seen in 20-30%
- Monomorphic population of prolymphocytes present (intermediate sized cells, moderately diffuse nuclear chromatin with prominent nucleolus, medium to high N:C ratio with mildly basophilic cytoplasm)
- >55% of lymphocytes must be prolymphocytes.
- Immunophenotype: CD19+, CD20+, CD22+, CD79a+, CD23 in 10-20%. CD200 usually negative. Strong SIg.
- Complex karyotypes, del(17)p/ TP53 mutations common.

4) Marginal zone
- CD5 positivity seen in up to 20% of cases of MZL
- Monomorphic population of intermediate sized lymphoid cells with mature nuclear chromatin and a high N:C ratio. Bipolar cytoplasmic fimbriae in SMZL.
- Nodular or diffuse infiltration on trephine. Can form a germinal centre. Intrasinusoidal in SMZL.
- Immunophenotype not specific: positive for CD19, CD20, CD22, CD79a and SIg. CD10- and usually negative for CD23 and CD200.
- No specific diagnostic features. Often a diagnosis of exclusion. del(7q) seen in a subset and is rare in other LPDs.

5) LPL
- CD5 positivity seen in up to 20% of cases of LPL
- Plasmacytic differentiation present: plasmacytoid lymphocytes present as well as plasma cells (with normal, mature morphology). Increased mast cells (with normal morphology) on aspirate sample.
- Interstitial or diffuse infiltration on trephine. Plasma cells admixed.
- Immunophenotype not specific: positive for CD19, CD20, CD22, CD79a and SIg. CD10- and usually negative for CD23 and CD200.

6) CD5+ DLBCL
- CD5 positivity in 5-10% of DLBCL, usually ABC phenotype.
- Large immature lymphoid cells. Can be pleomorphic.
- High forward scatter on flow cytometry. CD19+, CD20+, CD22+, CD79a+. CD10+/-. High Ki67.
- MYC, BCL2, BCL6 overexpression, translocation variable.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List the immunophenotypic/ genetic features of hairy cell leukaemia

A
  • Flow cytometry: high side scatter. Bright sIg, CD20, CD22 and CD11c. CD25, CD103, CD123 and CD200 positive. FMC7 positive. Usually CD10 negative
  • Annexin 1 positive (most specific marker)
  • B-RAF V600E
  • TBET.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Discuss monoclonal B lymphocytosis

A
  • Refers to a clonal lymphocyte count <5x10^9 in the peripheral blood without any clinical symptoms or signs (cytopenia, lymphadenopathy, hepatosplenomegaly) of an underlying LPD.
  • Divided into those with a CLL phenotype vs those with a non-CLL phenotype (associated with a worse prognosis, must exclude an underlying LPD)
  • Divided into low count (<0.5x10^9) and high count (>0.5x10^9) MBL
  • In those with a CLL MBL, low count is associated with a good prognosis with a very low rate of clinical progression.
  • High count CLL MBL is identical to CLL Rai stage 0/ Binet stage A and has a rate of progression to CLL that is 1-2% per year.
  • Some MBLs may be transient/ self-limited
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some of the features of unmutated CLL

A
  • Unmutated CLL is thought derive from an antigen naïve B cell that has not experienced the germinal centre
  • Associated with more aggressive disease, chemotherapy resistance and reduced overall survival.
  • Advanced stage (C, III, IV)
  • Lymphocyte doubling time <12 months
  • High ZAP70
  • High CD38
  • High B2MG
  • High-risk cytogenetics (del(17p), complex karyotype)
  • Higher rates of clonally related Richter’s transformation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List the poor prognostic features of CLL

A

1) Clinical
- Age
- Male sex
- CIRS score >6
- Clinical stages (lymphadenopathy, splenomegaly)

2) Lab/ Morphology
- Thrombocytopenia (<100)
- Anaemia (<100- 110)
- Lymphocyte doubling time <12 months
- Increased LDH, B2M
- Atypical morphology
- Diffuse pattern of BM infiltration
- Expanded proliferation centre
- Clonally related Richter’s transformation

3) Immunophenotype
- ZAP70 positive
- CD38 positive
- CD49d positive

3) Molecular
- Del(17p)/ TP53 mutations, complex karyotype
- Unmutated IGHV
- NOTCH1, MYC mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Richter’s transformation. What different types are there?

A
  • Transformation of CLL to an aggressive diffuse large B cell lymphoma or Hodgkin’s lymphoma

1) DLBCL= most common (2-8% of CLL patients)
- Clonally related= most common= worse prognosis
- Most common in those with unmutated IGHV.
- Associated with mutations in TP53, MYC, CDKN2A and NOTCH1
- Clonally unrelated= least common= same prognosis as de novo DLBCL
- Most common in those with mutated IGHV.

2) Hodgkin’s Lymphoma
- 50% clonally unrelated
- Thought to arise out of immunosuppression due to CLL and therapy
- More common in those with mutated IGHV.
- Poorer prognosis than de novo Hodgkins lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

List the mutations most commonly seen in CLL and the associated prognosis

A

1) Del(13q)
- 25-40%
- Good prognosis. Average survival >15 years.

2) Trisomy 12
- 15-20%
- Associated with atypical morphology.
- Shorter treatment free survival.

3) Del(11q)
- 20-25%.
- Shorter time to progression.

4) Del(17p)
- 5- 10%
- Associated with unmutated IGHV, TP53 mutations, clonal evolution, complex karyotype.
- Associated with resistance to chemotherapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

List the Rai and Binet stages in CLL

A
Rai staging: 
Stages 0-IV 
- 0= isolated lymphocytosis
- 1= + lymphadenopathy 
- 2= and/or spleen/liver 
- 3= and/or anaemia
- 4= and/or thrombocytopenia 
OS ranges from >15yrs to 3-5yrs.

Binet staging:

  • A isolated lymphocytosis
  • B >3 lymphoid areas
  • C anaemia/ thrombocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is a diagnosis of atypical CLL made?

A
  • Atypical morphology: cleaved forms, prolymphocytes, large/ immature cells present and comprise >15% of total lymphocytes.
  • Atypical immunophenotype: can be CD5-, CD23-, Sig+ (strong) and FMC7+. Usually CD200 positive.
  • Associated with trisomy 12
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is grade 3 follicular lymphoma?

A

Defined by the presence of more than 15 centroblasts per HPF

  • Grade 3A: centrocytes also present.
  • Grade 3B: centrocytes absent

Ki67 often >20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the hallmark features of follicular lymphoma?

How do these features differ across the different grades of follicular lymphoma?

A
  • Germinal centre B cell that has undergone VDJ rearrangement
  • BCL2 over-expression with t(14;18) in 85-90%
  • CD10 positive (rare in other small cell lymphomas)
  • Aberrations in chromatin modifiers: KMT2D, CREBBP, EZH2
  • Grade 3 follicular lymphoma, especially grade 3B, is more likely to be CD10-, BCL2-, MUM1/IRF4+ and BCL6+ than grade 1/2 FL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List the prognostic features of follicular lymphoma

A
  • FLIPI: age >60, Hb <120, stage III or IV, >4 nodal sites, raised LDH
  • Grade 3 disease
  • Aberrations in TP53, MYC translocations.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

List the 4 subtypes of follicular lymphoma and the important features of these subtypes

A

1) Testicular follicular lymphoma
- Children and young adults
- Cytologically high grade (usually 3A)
- Lack t(14;18)

2) In situ follicular neoplasia
- Colonisation of germinal centres by B cells with t(14;18)
- If incidentally found: <5% risk of progression to FL
- Higher rates of progression if there are high numbers of FL like cells in the PB.

3) Duodenal type follicular lymphoma
- t(14;18) present within clonal B cells
- Low grade with few centroblasts present
- Good prognosis

4) Paediatric FL
- Children and young adults
- Head and neck lymph nodes. Single site of disease common
- Lack t(14;18)
- Appear high grade, high proliferation rate
- Excellent prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Marginal zone lymphoma can be a diagnosis of exclusion. List the flow cytometry and immunohistochemical markers that can be performed to exclude other low grade LPDs.

A
  • Flow cytometry: CD5-, CD10-, CD23-, CD200-, CD103-. Strong expression of SIg and the B cell markers.
  • IHC: BCL6-, CCND1-, SOX11-, LEF1- and annexin A1 negative.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Discuss the genetic profile of MALT

A
  • IGHV rearranged
  • Biased IGHV gene usage
  • Chromosomal translocations involving involving MALT1 on chromosome 18 and IgH on chromosome 14 are present in a subset
    • t(11;18): chimeric protein BIRC3-MALT1
    • t(1;14): transcriptional deregulation of BCL10
    • t(14;18): transcriptional deregulation of MALT1
    • t(3;14); transcriptional deregulation of FOXP1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What immunohistochemical stains, if positive, can be helpful in the diagnosis of MZL?

A

IRTA1 and MNDA

17
Q

List the lymphomas that can demonstrate an intrasinusoidal pattern of bone marrow infiltration

A
  • Splenic marginal zone lymphoma
  • Nodal marginal zone lymphoma
  • Splenic diffuse red pulp small B cell lymphoma
  • Hairy cell variant
  • Intravascular lymphoma
  • Hepatosplenic T cell lymphoma
  • T-cell LGL
18
Q

How is the immunophenotype of hairy cell variant the same and how is it different from hairy cell leukaemia?

A
  • Similarities: Pan B cell expression, CD11c, CD103 and strong SIg positive.
  • Differences: CD25, CD200, CD123 and annexin A1 negative. Bright CD72.
19
Q

What lymphomas can show plasmacytoid differentiation?

A
  • Lymphoplasmacytic lymphoma/ Waldenstroms Macroglobulinaemia
  • Marginal zone lymphoma
  • Follicular lymphoma
  • Angioimmunoblastic T cell lymphoma
20
Q

List the poor prognostic markers in LPL/ WM

A
  • Age
  • Cytopenia
  • Elevated LDH and/ or B2M
  • High serum paraprotein
  • CXCR4 mutations (seen in 30%-40%)
  • TP53 aberrations
21
Q

What are the diagnostic features of cold agglutin disease?

A
  • Monoclonal IgM kappa
  • Nodular pattern of infiltration without a significant plasmacytic cytology or reactive mast cell population.
  • Plasma cells surrounding aggregates and within the interstitium rather than admixed with the lymphoid population.
  • Median infiltration ~10%
  • Flow cytometry pattern: kappa light chain restricted B lymphocytes CD20+, IgMs+/IgDs+, CD27+, CD5-/+, CD11c-, CD23-, CD38-.
  • Highly restricted IGHV and light chain usage that differs from that seen in WM)
  • KMT2D and CARD11 mutations
  • No MYD88
22
Q

What are the features of leukaemic non-nodal mantle cell lymphoma?

A
  • Isolated spleen, bone marrow and peripheral blood involvement
  • No nodal involvement
  • Non-blastoid or pleomorphic morphology
  • CCND1 positive, SOX11 negative
  • Low Ki67 <10%
  • Mutated IGHV genes
23
Q

What are some of the poor prognostic features seen in mantle cell lymphoma?

A
  • Age
  • Raised LDH
  • Raised WCC
  • ECOG >1
  • Ki67 >30%
  • Unmutated IGHV
  • Blastoid or pleomorphic morphology
  • TP53 aberrations/ del(17p)
  • SOX11 positivity (in some but not all studies)
24
Q

What is the Hans algorithm and why is it used?

A
  • Gene expression profiling in DLBCL has shown three distinct subtypes of DLBCL with different prognosis
  • Germinal centre phenotype: good prognosis 80% 3 yr survival
  • Activated B cell phenotype: poor prognosis: 45% 3 year survival
  • Unclassified.
  • Gene expression profiling is expensive and available only in specialised laboratories.
  • The Hans algorithm uses immunohistochemistry to determine cell of origin. It is used as a surrogate for GEP studies.
  • CD10 positive cases as classified as GCB
  • CD10-, BCL6+, MUM1/IRF4- cases are classified as GCB
  • CD10-, BCL6- are classified as non-GCB
  • CD10-, BCL6+, MUM1/IRF4+ are classified as non-GCB
  • 86% concordance with GEP. Sensitivity of 85-90% for GCB subtype.
25
Q

List the four genetic subtypes of DLBCL and the key features of the different subtypes

A

1) MCD: MYD88 and CD79b mutations
- Seen predominately in ABC subtype
- High reliance on chronic active B-cell receptor signalling
- Poor outcome. 5yr OS 26%

2) BN2: BCL6 fusions and Notch2 mutations
- Equally distributed across ABC and unclassified subtypes
- Also rely on chronic active B-cell receptor signalling via NF-KB
- Associated with a better outcome. 5yr OS 65%

3) N1: Notch1 mutations
- Seen predominately in the ABC subtype.
- Associated with a poor outcome: 5yr OS 36%

4) EZB: EZH2 and BCL2 translocations
- Seen predominately in the GCB phenotype.
- Associated with a favourable outcome: 5yr OS 68%

26
Q

What is double hit/ triple hit DLBCL

A
  • DLBCL with CMYC and BCL2 and/ or BCL6 gene rearrangements.
  • Poorer prognosis when compared to non DH/ TH DLBCL: more intensive treatment used (DA-EPOCH-R vs R-CHOP)
  • Prognosis of CMYC/ BCL6 DH debated: some data suggests that the prognosis is not as poor as CMYC/BCL2 rearranged although more recent data (Lunenburg analysis) suggests that prognosis is just as poor.
  • CMYC/ BCL2 occur almost exclusively in GCB phenotype
  • CYMC/BCL6 occur almost exclusively in ABC phenotype
  • CMYC occurs equally in both subtypes
27
Q

What are the approaches to FISH testing in DLBCL

A

1) Screen all DLBCL treated with curative intent ( ESMO guidelines)
2) Screen all GCB DLBCL: will miss ~1/3rd of cases (most of which will be BCL6/CMYC, NCCN)
3) Screen all double expressor DLBCL: will miss ~1/3rd of cases
4) Screen all for CMYC, proceed to BCL2 and BCL6 if positive

Cannot use high Ki67 or high clinical risk factors.

28
Q

List the poor prognostic features in DLBCL

A
  • High IPI score
    • Age >60
    • ECOG >1
    • > 1 extra nodal sites
    • Stage III or IV
    • LDH elevated
  • Male sex
  • Concordant bone marrow involvement
  • CNS involvement
  • ABC phenotype (likely MCD and N1)
  • CD5+
  • CMYC with an IGH partner
  • Double expressor
  • (Double hit)
29
Q

What is the immunophenotype of PMBCL

A
  • CD30+, CD23+, MUM1/IRF4+, CD15-

- Should not have CMYC, BCL2, BCL6 rearrangements

30
Q

What is the immunophenotype of BL

A
  • Germinal centre B cell origin: Strong SIg expression with light chain restriction and expression of pan B-antigens.
  • Expression of GC markers CD10 and BCL6
  • Overexpression of CMYC
  • Ki67 ~100%
  • BCL2 negative (distinguishes from DLBCL)
  • TDT negative (distinguishes from B-ALL)
31
Q

Discuss the genetics of BL

A
  • Characterised by the MYC translocation: most commonly t(8;14): with IgH
    • Other translocations involve lambda light chain
      (22q) or less commonly kappa (2p)
  • Simple karyotype
  • Gain of 1q= most common additional karyotypic abnormality
  • In addition to being translocated, MYC is the most common gene mutated in BL
  • ID3 and TCF3 mutations are common in sBL: result in antigen independent signalling through the BCR
  • Cell cycle genes such as CCND3 and CDKN2A mutations are also commonly seen
  • TP53 aberrations in 55% of sBL
32
Q

What is Burkitt like lymphoma with 11q aberrations?

A
  • Clinical, morphologic, immunophenotypic, gene expression and prognostic profile of BL BUT lack a demonstrable MYC translocation by FISH
  • Characterized by an interstitial 11q23 gain immediately followed by a telomeric loss at 11q24
  • Can have more complex karyotypes than classical BL